Getting denied coverage for Humira is disorienting because the denial could mean very different things depending on your situation.

If you're a new patient, it likely means your insurer wants you to try cheaper alternatives first. If you've been stable on Humira for months or years, it might mean your insurer removed it from the formulary entirely and is pushing you toward a biosimilar you never asked for. And while biosimilars are clinically similar to Humira, "similar" doesn't mean identical — some patients experience differences in side effects, delivery devices, or how well the medication controls their condition.

Since 2024, all three major pharmacy benefit managers have been removing brand-name Humira from their commercial formularies. CVS Caremark dropped it in April 2024. Express Scripts followed for 2025. OptumRx did the same. In their place: biosimilars like Hyrimoz, Amjevita, Cyltezo, and Hadlima. The result is a wave of denials that simply didn't exist two years ago.

The good news is that you can appeal, and appeals work far more often than most people realize. The right approach depends on which type of denial you're facing. And because Humira is approved for so many conditions — rheumatoid arthritis, Crohn's disease, psoriasis, and more — the step therapy requirements can vary dramatically depending on your diagnosis.

This article explains why your Humira coverage was denied, how to match your denial type to the right response, and what to include in an appeal that actually gets results.

Why Insurance Denies Humira Coverage

Before you do anything else, identify the specific reason your insurer denied coverage. The denial reason determines your entire appeal strategy, and submitting the wrong type of response wastes time and can exhaust your limited appeal opportunities.

Broadly, Humira denials fall into two camps: patients who are already stable on Humira and are being forced onto a biosimilar, and new patients trying to get coverage for the first time. Both face real barriers, but the barriers are different, and so are the solutions.

What Makes Humira Denials Different from Other Medications

Humira is approved for nine or more autoimmune disorders, including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, severe chronic plaque psoriasis, severe hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. Each condition has completely different step therapy requirements. A denial for a Crohn's patient and a denial for a psoriasis patient may use identical language but require totally different appeal strategies. A blanket response that doesn't address your specific condition's requirements will almost certainly fail.

Humira is also a biologic, not a pill. That means safety screenings — a TB test, a hepatitis B panel — are required before treatment can start. Missing or incomplete lab results are one of the most common and most preventable reasons for Humira prior authorization denials. If your denial traces back to missing screenings, you may not need a formal appeal at all. A corrected resubmission with the lab results included can resolve it.

And then there's the biosimilar shift. Many Humira denials in 2025 and 2026 aren't about whether you need adalimumab. They're about whether your insurer will pay for the brand-name version or require you to use a lower-cost alternative. When your insurer removes Humira from its formulary and replaces it with Hyrimoz or Amjevita, that's a business decision, not a medical one.

The Denial Types You're Most Likely to Encounter

Most articles about Humira denials list reasons using the language insurers put in their letters. That's not especially helpful. What matters is what the denial actually means for you and how it shapes your next move.

A note before you start building your appeal: not every denial requires one. If your denial traces back to a correctable administrative error — missing safety screenings, an incorrect ICD-10 code, or an outdated billing code — a corrected resubmission is often faster and more effective than a formal appeal. One common billing issue right now: the HCPCS code for adalimumab changed from J0135 to J0139 as of January 2025. If your provider's billing system hasn't been updated, that alone can trigger a denial.

Formulary Change and Biosimilar Switch Denials

This is the denial type driving the most confusion and frustration right now. If you've been stable on Humira and received a letter saying it's no longer on your plan's formulary, you're not alone.

CVS Caremark removed brand Humira from its major national commercial formularies in April 2024, replacing it with biosimilars. Express Scripts did the same beginning in 2025, and OptumRx followed with its own biosimilar-first strategy. The practical effect: millions of patients who had stable coverage woke up to letters telling them their medication was no longer preferred.

The insurer's position isn't irrational. Biosimilars are clinically similar to Humira, and for many patients, switching works fine. But "many patients" isn't all patients. A 2026 analysis of Truveta electronic health record data found that among patients who switched from brand Humira to a biosimilar, 13.2% ultimately switched back to the original. Nearly 40% of those switchbacks happened within 30 days, suggesting early dissatisfaction, side effects, or problems with the transition.

If you have a clinical reason for staying on brand Humira, the strongest arguments for a formulary exception include: adverse reactions to a biosimilar's inactive ingredients or delivery device, a documented history of disease flares during medication switches, immunogenicity concerns such as developing antibodies during transitions, and adherence and consistency factors for chronic conditions where stability matters.

It's also worth knowing that manufacturer support programs are evolving alongside this biosimilar transition. AbbVie's patient assistance landscape for Humira is shifting as biosimilars become the standard formulary option, which makes understanding your appeal rights more important than ever. If copay support that previously helped cover your costs is changing, an approved appeal that restores insurance coverage is the most reliable path forward.

Step Therapy Required (Conventional Medications)

Step therapy means your insurer requires you to try and fail on older, cheaper medications before approving Humira. Even when your doctor has clinical reasons for prescribing it directly.

What makes this especially complicated for Humira is that step therapy requirements are completely different depending on your diagnosis. A rheumatoid arthritis (RA) patient typically needs to fail on one or two conventional DMARDs like methotrexate. A plaque psoriasis patient may need to fail topical agents and a conventional systemic. A patient with ankylosing spondylitis usually needs to try two or more NSAIDs first. Knowing what your insurer expects for your specific condition is essential before you build your appeal.

"Failure" doesn't always mean the drug didn't work. Side effects, contraindications, and medical reasons a drug is inappropriate all count. Methotrexate, for example, is contraindicated in pregnancy and may not be safe for patients with liver disease. If your doctor knows you can't take a required step therapy drug, that should be documented clearly in your appeal rather than forcing you through a trial that's medically inappropriate.

When an insurer demands you fail on conventional therapies before accessing Humira, they may be contradicting leading medical society guidance. The American College of Rheumatology's 2021 guidelines for RA support biologic therapy for patients who don't achieve their treatment target on conventional DMARDs like methotrexate. If you've already tried and failed the medications your insurer's step therapy requires, citing these guidelines puts the insurer's demand for additional steps in tension with the clinical evidence. The 2025 American College of Gastroenterology guidelines for Crohn's disease go further, explicitly recommending against the traditional step-up approach and supporting early use of advanced therapies for patients with moderate-to-severe disease. Citing these guidelines in your appeal is a powerful argument at any stage of the process.

Biosimilar Step Therapy

This is distinct from conventional step therapy. Here, the insurer will cover adalimumab — they just want you to try a preferred biosimilar (typically Hyrimoz, Amjevita, or Cyltezo) before brand Humira.

The practical question is straightforward: is there a clinical reason you specifically need the brand? If you've been stable on brand Humira and have documented reasons why switching poses risk — adverse reactions, immunogenicity concerns, prior failed switches — then document those reasons thoroughly and appeal. If you haven't tried a biosimilar and don't have a clinical contraindication, trying the preferred biosimilar may be the fastest path to treatment.

PA Requirements Not Met (Not Medically Necessary)

This denial often means the initial submission was too thin, not that the insurer fully reviewed your case and made a considered medical judgment. Common gaps include not specifying disease severity with objective measures (DAS28 scores for rheumatoid arthritis, CDAI for Crohn's, PASI or BSA for psoriasis), not listing prior failed therapies with dates and specific outcomes, and not explaining how your symptoms and disease progression make Humira the appropriate next step for your situation.

Because Humira treats so many conditions, the documentation requirements differ by diagnosis. A prior authorization that doesn't clearly link your specific condition, its severity, your treatment history, and the insurer's criteria for that indication will almost always trigger this denial. The fix is usually more thorough documentation, not a different argument.

How to Appeal a Humira Denial (Step by Step)

Appeals work far more often than most people think. Insurance companies have spent decades conditioning patients to accept "no" as final. It's not. Fewer than 1% of insurance denials are ever appealed, and insurers count on that. When patients do appeal with the right evidence and documentation, overturn rates are significant.

Step 1: Read Your Denial Letter Carefully

Your denial letter is required by law to include the reason for denial, your appeal rights, and your deadline to appeal. Read it closely and identify which denial type from the table above matches your situation. If anything in the letter is unclear, you have the right to request and review your full claim file from your insurer.

Pay close attention to your deadline. Most commercial insurance plans allow 180 days to file an appeal, but UnitedHealthcare gives just 65 calendar days for commercial plan member-initiated appeals — the shortest window among major insurers. Medicare Advantage plans follow CMS rules at 60 days. Missing your deadline forfeits your appeal rights regardless of how strong your case is.

Step 2: Understand That You Can Appeal — Not Just Your Doctor

Many patients assume their doctor has to handle the appeal. Your doctor's prior authorization or provider appeal is one process. Your patient-initiated appeal is a separate process with its own protections. Here's why you should appeal yourself, not just leave it to your doctor.

Patient appeals carry stronger legal protections than provider appeals: mandated response timelines, the right to external review by an independent third party, and multiple levels of appeal. If your doctor's PA was denied, your appeal is a separate opportunity. Use it.

Step 3: Confirm Your Clinical Documentation Is Complete

Before building your appeal, run through the basics. Is the diagnosis coded correctly with current ICD-10 codes for your specific indication? Are all required safety screenings (TB test, hepatitis B panel) documented and included? Is the billing code current (J0139 as of January 2025, not the old J0135)?

For patients being switched off brand Humira: is your doctor willing to document your clinical stability on the current medication with specific metrics? Disease activity scores, lab values, and functional assessments all strengthen an appeal for continuity of care.

If the issue is a correctable administrative error, a resubmission may resolve it without a formal appeal, and it's faster.

Step 4: Get a Letter of Medical Necessity

This is the single most important document in your appeal. A strong letter of medical necessity from your prescribing physician should include your diagnosis with ICD-10 codes and current disease severity scores, your full prior medication history with specific reasons each therapy was stopped (inefficacy, side effects, contraindications), and clear clinical rationale for why Humira is the appropriate treatment.

For biosimilar switch appeals specifically, the letter should also document your clinical improvement on brand Humira with measurable outcomes and explain why switching introduces risk for your situation.

If your doctor hasn't written one before or seems unsure what to include, be direct. Offer to provide an outline of what insurers typically look for, or review how to talk to your doctor about a denial so you're prepared for the conversation. Many physicians are willing to write a strong appeal letter but don't always know the specific documentation that moves the needle with insurance reviewers.

Step 5: Build Your Appeal Package

A complete appeal package brings together four components:

Your cover letter states what you're appealing, which denial you're responding to, and what outcome you're requesting.

Your letter of medical necessity from your physician provides the clinical backbone.

Your clinical documentation includes relevant medical records, lab results, imaging, and disease severity assessments. Reference authoritative peer-reviewed clinical guidelines where they support your case: ACR guidelines for rheumatoid arthritis, AGA guidelines for Crohn's disease and ulcerative colitis, AAD guidelines for psoriasis and hidradenitis suppurativa.

Your personal statement explains how the denial affects your daily life, your health, and your ability to function. This is where you tell your story in your own words. Insurers are required to consider all submitted evidence during an appeal, and a clear personal narrative about the real-world impact of losing your medication adds weight that clinical documents alone can't provide.

Together, these form the three pillars of a winning appeal: your story, the clinical evidence, and the policy and legal analysis that shows your situation meets the plan's own criteria.

Step 6: Submit and Track

Submit your appeal according to the instructions in your denial letter. Your insurer must respond within 30 days for a standard internal appeal, or within 72 hours for an urgent or expedited appeal (when your health would be seriously jeopardized by waiting).

Keep records of everything: your submission method, date, confirmation numbers, and the name of anyone you speak with. If you submit by fax, keep the transmission confirmation. If you mail it, use certified mail with return receipt. If you don't receive a response within the required timeframe, here's what to do if you haven't heard back about your appeal.

Step 7: Escalate If Needed

If your internal appeal is denied, you have the right to an external review by an independent third party. This is a reviewer who evaluates the medical justification for your treatment, not whether the insurer wants to pay for it. External reviews are binding on the insurer in most states.

Some states also have additional protections worth knowing about. Several states have step therapy exception laws, and a growing number have enacted protections related to non-medical switching of biologic therapies. Check whether your state offers these protections before assuming you've exhausted your options.

Don't give up after one "no." The appeals process is designed with multiple levels for a reason. Persistence is part of the strategy, and each level of appeal brings a fresh set of eyes to your case. If you're feeling discouraged, here's why you shouldn't give up after a denied appeal.

An Easier Path: Let Claimable Handle Your Humira Appeal

If navigating this process feels overwhelming, or you don't have the time to research insurer policies and build a clinical case from scratch, Claimable can handle it for you.

Here's how it works:

1. Answer a few questions about your Humira denial and medical history.
2. We build your case using our database of millions of clinical studies, insurer policies, and legal standards.
3. We create a fully customized appeal package with your personal story, clinical evidence, and policy analysis.
4. We submit it for you — faxed and mailed directly to your insurer.
5. We guide you through escalation if needed.

Over 80% of Claimable appeals succeed, with most cases resolved in 10 days or less.

Appealing with Claimable for Humira costs $39.95. No success fees, no hidden costs, just a flat fee. When brand Humira can cost nearly $7,000 per month without insurance coverage, the math is simple.

Start your Humira appeal →

Appeal Timelines: How Long Does a Humira Appeal Take?

Typical timelines for each stage of the Humira insurance appeal process.

The faster you submit a complete, well-documented appeal, the faster you'll get a decision. The average Claimable appeal gets a response in just 10 days.

Frequently Asked Questions

Why was my Humira denied if my plan used to cover it?

Since 2024, all three major pharmacy benefit managers — CVS Caremark, Express Scripts, and OptumRx — have removed brand Humira from their commercial formularies in favor of lower-cost biosimilars. Your plan may still cover adalimumab, but the prior authorization process for the brand-name version now typically requires a formulary exception with clinical justification. "Covered" and "approved without a fight" are no longer the same thing for Humira.

Can I appeal a Humira denial myself, or does my doctor have to do it?

You can appeal yourself. Patient-initiated appeals are a separate process from provider appeals, and they carry their own legal protections including mandated response timelines and the right to external review. If your doctor's prior authorization was denied, your patient appeal is an additional opportunity, not a duplicate.

What if my insurer wants me to switch to a Humira biosimilar?

It depends on your clinical situation. If you've been stable on brand Humira and have documented reasons why switching poses risk — adverse reactions to a biosimilar, disease flares during prior medication changes, immunogenicity concerns — that's a strong case for a formulary exception. If you haven't tried a biosimilar and don't have a clinical contraindication, trying the preferred biosimilar may be the fastest path to treatment. Either way, understanding your options before responding to the denial is important.

My insurance changed my Humira coverage mid-year. Is that legal?

Insurers can update their formularies, and many did so aggressively in 2024 and 2025 as biosimilar competition expanded. However, some states have enacted step therapy protections and non-medical switching restrictions that may limit an insurer's ability to force patients off stable biologic therapy for purely cost-driven reasons. Check whether your state has these protections, and reference them in your appeal if applicable.

Is it worth appealing a Humira denial?

Yes. Fewer than 1% of insurance denials are ever appealed, and insurance companies count on patients accepting the initial "no." But when patients appeal with proper clinical documentation, clear evidence of medical necessity, and an understanding of their legal rights, overturn rates are significant. The process takes effort, but the alternative — abandoning a treatment that manages a serious chronic autoimmune disorder — carries real health consequences.

Claimable's physician-led team has helped patients recover over $30 million in care access by fighting insurance denials. We're SOC 2 Type II certified and HIPAA compliant. Learn more about how Claimable works →